PolyPid Ltd.
PolyPid Ltd. (PYPD): 1 pipeline candidate · 4 clinical trials. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
0% dilution
Lead: Phase 3
1 candidate
N/A
N/A
A transparent, data-derived signal for PolyPid Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$89.4M
Cash
$6.6M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| d-plex | Phase 3 |
Frequently asked questions
How many drug candidates are in PolyPid Ltd.'s pipeline?
PolyPid Ltd. (PYPD) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is PolyPid Ltd.'s lead drug candidate?
PolyPid Ltd.'s most advanced tracked candidate is d-plex (Phase 3) for Surgical Site Infection; Abdominal Surgery; Postoperative Wound Infection Superficial Incisional.
What is PolyPid Ltd.'s market capitalization?
PolyPid Ltd.'s market capitalization is approximately $89.4M.
Who is the CEO of PolyPid Ltd.?
Ms. Dikla Czaczkes Akselbrad is the chief executive officer of PolyPid Ltd. (PYPD).
Get the full picture on PolyPid Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.